Skip to content

INFINITY PHARMA

Active
Public limited companyfounded 1976active for 49 yearsVenecoweg 20A, 9810 Nazareth-De Pinte, BelgiumKBO/BCE: BE 0416.616.681
Summary

INFINITY PHARMA has been active since 1976 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.4m and a net result of -€231,419. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 91% of 6,172 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysisFollow ReportCompare
INFINITY PHARMAActiveChecked score 86/100
Risk analysis ReportCompare

Overview

Overview

Official details

Source: KBO
Status
Active since 08-12-1976 Normal situation
Activity
Wholesale of pharmaceutical and medical goods NACE 46460
Joint committees
207 Paritair Comité voor de bedienden uit de scheikundige nijverheid
116 Paritair Comité voor de scheikundige nijverheid · annual accounts 2025
Establishment unit
2.013.193.230 9810 Nazareth-De Pinte, since 31-03-1992
Financial year end
31 December
Peppol
Reachable since 01-10-2025
Company details

Board and ownership

Board
and 1 other
Shareholders
Holdings
Shares in 3 companies including FAGRON BELGIUM and FAGRON COMPOUNDING SERVICES
Board & ownership

Financial position

86 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Annual accounts 2025
Turnover
€10.7m
▲ 0.6%
Loss
€231,419
▼ 71.9%
Equity
€16.4m
▲ 29.8%
Total assets
€18.8m
▲ 17.8%
Employees on 31-12-2025
13
▼ 13.3%
Financials
Score breakdownraises riskLiquidity: current ratio 1.44, cash €688,3361 of the last 3 accounts latelowers riskFounded in 1976Equity €16.4m (87.2% of total assets)Show the evidence

Checked score

Score 2025
86 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 61% of small companies in wholesale trade (NACE 46)
Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Strong
Solvency 100=
equity 87.2% of total assets
Liquidity 53+9
short-term debt 12.8% · cash 3.7%
Profitability 20+10
return on assets -1.2%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,372 companies, NACE 46, small)
Last 24 months 12-2024: 3.3% 01-2025: 3.3%● unchanged vs 12-2024 02-2025: 3.2%▼ -0.1 percentage points vs 01-2025 03-2025: 3.3%▲ +0.1 percentage points vs 02-2025 04-2025: 3.3%● unchanged vs 03-2025 05-2025: 3.3%● unchanged vs 04-2025 06-2025: 3.3%● unchanged vs 05-2025 07-2025: 3.4%▲ +0.1 percentage points vs 06-2025 08-2025: 3.5%▲ +0.1 percentage points vs 07-2025 09-2025: 3.6%▲ +0.1 percentage points vs 08-2025highest value 10-2025: 0.6%▼ -3.0 percentage points vs 09-2025 11-2025: 0.6%● unchanged vs 10-2025 12-2025: 0.6%● unchanged vs 11-2025 01-2026: 0.6%● unchanged vs 12-2025 02-2026: 0.6%● unchanged vs 01-2026 03-2026: 0.6%● unchanged vs 02-2026 04-2026: 0.6%● unchanged vs 03-2026 05-2026: 0.6%● unchanged vs 04-2026 06-2026: 0.6%● unchanged vs 05-2026 07-2026: 0.3%▼ -0.3 percentage points vs 06-2026lowest value 08-2026: 0.3%● unchanged vs 07-2026lowest value 09-2026: 0.3%● unchanged vs 08-2026lowest value 10-2026: 0.3%● unchanged vs 09-2026lowest value 11-2026: 0.3%● unchanged vs 10-2026lowest value
Credit of up to €1,050,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.44 (1.06 in 2024), below the usual 1.5. Short-term debt is 12.8% and cash 3.7% of total assets. 12.8% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 92% of them on solvency, 69% on liquidity, 13% on profitability and 68% on growth.

The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 1.44, cash €688,336
NBB · annual accounts
lowers risk · Founded in 1976
Companies that have existed this long fail less often. How much that weighs depends on the rest of the company's profile.
KBO
lowers risk · Equity €16.4m (87.2% of total assets)
NBB · annual accounts
raises risk · 1 of the last 3 accounts late
NBB · filings
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
50 days early
2024
46 days late
2023
54 days early
2022
56 days early
2021
61 days early
2020
67 days early
2019
61 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 43 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Financials

Financials · financial year 2025, full format

Annual accounts 2025 filed on 11-06-2026 PDF all 49 filings

Turnover
€10.7m▲ 0.6%
2024 · €10.7m
EBIT margin
-0.7%▲ 4.3pp
2024 · -5.0%
Net result
-€231,419▲ 71.9%
2024 · -€822,517
Working capital
€1.1m▲ 425%
2024 · €200,859
In the rankings #7 company by equity in Nazareth-De Pinte, Wholesale and retail trade sector#8 company by total assets in Nazareth-De Pinte, Wholesale and retail trade sector
Multi-year overview
2018 to 2025, 8 financial years
Turnover
€10.7m
▲ 0.6% 2025
20182025
Operating result
-€72,613
▲ 86.3% 2025
20182025
Net result
-€231,419
▲ 71.9% 2025
lowest quarter of the sector
20182025
EBIT margin
-0.7%
▲ 4.3pp 2025
20182025
Equity
€16.4m
▲ 29.8% 2025
highest quarter of the sector
20182025
Total assets
€18.8m
▲ 17.8% 2025
highest quarter of the sector
20182025
Debt
€2.4m
▼ 27.8% 2025
20182025
Working capital
€1.1m
▲ 425% 2025
middle half of the sector
20182025
Solvency
87.2%
▲ 8.1pp 2025
highest quarter of the sector
20182025
Current ratio
1.44
▲ 0.38 2025
middle half of the sector
20182025
Return on assets (ROA)
-1.2%
▲ 3.9pp 2025
lowest quarter of the sector
20182025
Staff (FTE)
13.6
▼ 31.3% 2025
middle half of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable unfavourable
Line20182019202020212022202320242025
Turnover€11.1m-€10.6m▼ 4.1%€15.7m▲ 47.7%€10.2m▼ 34.7%€7.2m▼ 29.8%€11.4m▲ 58.3%€10.7m▼ 6.2%€10.7m▲ 0.6%
Operating result€1.8m-€1.8m▼ 2.0%€2.2m▲ 21.8%-€0.5m-€0.05m▲ 88.0%-€0.3m▼ 427%-€0.5m▼ 85.7%-€0.07m▲ 86.3%
Net result€0.4m-€13.3m▲ 38×€28.4mabove the sector's middle half▲ 113%-€6.4mbelow the sector's middle half-€0.5mbelow the sector's middle half▲ 92.2%-€7.4mbelow the sector's middle half▼ 1,364%-€0.8mbelow the sector's middle half▲ 88.8%-€0.2mbelow the sector's middle half▲ 71.9%
EBIT margin16.7%-17.0%▲ 0.4pp14.0%▼ 3.0pp-4.4%▼ 18.4pp-0.8%▲ 3.6pp-2.5%▼ 1.8pp-5.0%▼ 2.5pp-0.7%▲ 4.3pp
Equity€3.0m-€9.4m▲ 209%€37.7mabove the sector's middle half▲ 303%€31.3mabove the sector's middle half▼ 17.0%€5.8mabove the sector's middle half▼ 81.4%-€1.6mbelow the sector's middle half€12.6mabove the sector's middle half€16.4mabove the sector's middle half▲ 29.8%
Total assets€59.4m-€66.0m▲ 11.0%€90.1mabove the sector's middle half▲ 36.6%€82.0mabove the sector's middle half▼ 8.9%€53.1mabove the sector's middle half▼ 35.3%€47.2mabove the sector's middle half▼ 11.1%€16.0mabove the sector's middle half▼ 66.2%€18.8mabove the sector's middle half▲ 17.8%
Debt€56.4m-€56.6m▲ 0.4%€52.3m▼ 7.5%€50.7m▼ 3.1%€47.3m▼ 6.8%€48.8m▲ 3.2%€3.3m▼ 93.2%€2.4m▼ 27.8%
Working capital-€48.2m--€41.8m▲ 13.3%€25.2mabove the sector's middle half€25.8mabove the sector's middle half▲ 2.3%-€7.2mbelow the sector's middle half-€14.1mbelow the sector's middle half▼ 97.2%€0.2mwithin the sector's middle half€1.1mwithin the sector's middle half▲ 425%
Solvency5.1%-14.2%▲ 9.1pp41.9%within the sector's middle half▲ 27.7pp38.2%within the sector's middle half▼ 3.7pp11.0%below the sector's middle half▼ 27.2pp-3.3%below the sector's middle half▼ 14.2pp79.1%above the sector's middle half▲ 82.4pp87.2%above the sector's middle half▲ 8.1pp
Current ratio0.14-0.26▲ 0.121.48within the sector's middle half▲ 1.221.51within the sector's middle half▲ 0.030.85below the sector's middle half▼ 0.660.71below the sector's middle half▼ 0.141.06below the sector's middle half▲ 0.351.44within the sector's middle half▲ 0.38
Return on assets (ROA)0.6%-20.2%▲ 19.6pp31.5%above the sector's middle half▲ 11.3pp-7.8%below the sector's middle half▼ 39.3pp-0.9%below the sector's middle half▲ 6.9pp-15.6%below the sector's middle half▼ 14.7pp-5.2%below the sector's middle half▲ 10.5pp-1.2%below the sector's middle half▲ 3.9pp
Staff (FTE)5.4-9.4▲ 74.1%9.6within the sector's middle half▲ 2.1%9.8within the sector's middle half▲ 2.1%9.8within the sector's middle half=19.1within the sector's middle half▲ 94.9%19.8within the sector's middle half▲ 3.7%13.6within the sector's middle half▼ 31.3%
above within below The sector band is the middle half of the companies in Wholesale trade (NACE 46). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.

The operating result for 2025 is a loss of €72,613, smaller than the loss of €531,006 in 2024.

Large changes and their cause
  • 2024 Net result +89% on 2023. Merger absorbing PHARMA-PACK, Official Gazette 08-08-2023, in the previous financial year. That operation now counts for a full year for the first time.
  • 2023 Turnover +58%, Net result -1,364%, Staff (FTE) +95% on 2022. Merger absorbing PHARMA-PACK, Official Gazette 08-08-2023.
  • 2022 Net result +92% on 2021. Merger absorbing INFINITY PHARMA, Official Gazette 26-07-2021, in the previous financial year. That operation now counts for a full year for the first time.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €18.8m
Fixed assets €15.3m ▲ 23.4%
Current assets €3.5m ▼ 2.1%
Equity and liabilities €18.8m
Equity €16.4m ▲ 29.8%
Debt €2.4m ▼ 27.8%
Debt's share of the balance-sheet total falls from 20.9% to 12.8%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€19,095▲
2024 · -€413,899
Cash flow
-€139,711▲
2024 · -€705,411
Quick ratio
0.41▲
2024 · 0.27
Debt to equity
0.15▼
2024 · 0.26
ROE
-1.4%▲
2024 · -6.5%
Interest coverage
0.35▲
2024 · -0.25
Debt ≤ 1 year
€2.4m▼
2024 · €3.3m
Income taxes
€3,500▲
2024 · -€1,081
Customer credit
9 days▼
2024 · 19 days
Supplier credit
128 days▼
2024 · 141 days
Staff costs
€1.5m▼
2024 · €2.0m
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.

Staff

social balance sheet
Item31-12-202131-12-202231-12-202331-12-202431-12-2025
Employees at the balance-sheet date109251513
full-time109171312
part-time--821
in full-time equivalents10924.114.512.9
Average over the year, in full-time equivalents9.89.819.119.813.6
On a permanent contract109251513
Joined1212003
Left1224105
Agency workers, average number0.20.12.21.10.1
Training hours11189344139172

Source: social balance sheet in the 2021 to 2025 annual accounts

Securities and guarantees

on own assets and for others
Item20212022202320242025
Guarantees given for others' debts€82.0m€53.1m€47.2m€15.9m€18.8m

Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item20212022202320242025
Tangible fixed assets€61,133€4,375€946,981€1,919€4,767
Intangible fixed assets€1.5m-€365,104€193,297€21,065
Financial fixed assets-€7.4m€6.5m-€4.0m
Depreciation and write-downs of the year€37,656€15,731€60,357€117,106€91,708

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Auditor

fees
Item20212022202320242025
Fee for the audit€31,951€17,000€18,020€29,000€19,000

Source: notes to the 2021 to 2025 annual accounts (relations with the auditor)

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 85 lines
Balance sheet Code20242025
Assets
Total assets20/58€16.0m€18.8m▲
Fixed assets21/28€12.4m€15.3m▲
Intangible fixed assets21€0.4m€0.3m▼
Tangible fixed assets22/27€0.04m€0.04m▼
Plant, machinery and equipment23€0.02m€0.02m▲
Furniture and vehicles24€0.005m€0.006m▲
Assets under construction and advance payments27€0.02m€0.02m▼
Financial fixed assets28€12.0m€15.0m▲
Affiliated companies280/1€12.0m€15.0m▲
Participating interests280€12.0m€15.0m▲
Other financial fixed assets284/8€0.003m€0.003m=
Amounts receivable and cash guarantees285/8€0.003m€0.003m=
Current assets29/58€3.5m€3.5m▼
Stocks and contracts in progress3€2.6m€2.5m▼
Stocks30/36€2.6m€2.5m▼
Raw materials and consumables30/31€0.8m€0.8m▼
Work in progress32€0-
Finished goods33€0.3m€0.5m▲
Goods purchased for resale34€1.6m€1.2m▼
Amounts receivable within one year40/41€0.7m€0.3m▼
Trade receivables40€0.6m€0.3m▼
Other amounts receivable41€0.2m€0.001m▼
Current investments50/53€0€0=
Own shares50€0€0=
Cash at bank and in hand54/58€0.2m€0.7m▲
Deferred charges and accrued income490/1€0.01m€0.04m▲
Equity and liabilities
Total equity and liabilities10/49€16.0m€18.8m▲
Equity10/15€12.6m€16.4m▲
Contributions10/11€9.3m€13.3m▲
Capital10€9.3m€13.3m▲
Issued capital100€9.3m€13.3m▲
Reserves13€4.2m€3.3m▼
Non-distributable reserves130/1€1.3m€1.3m=
Legal reserve130€1.3m€1.3m=
Own shares acquired1312€0€0=
Tax-exempt reserves132€0.02m€0.02m=
Distributable reserves133€2.8m€2.0m▼
Profit (loss) carried forward14-€0.8m-€0.2m▲
Amounts payable17/49€3.3m€2.4m▼
Amounts payable within one year42/48€3.3m€2.4m▼
Financial debts43€0€0=
Other loans439€0€0=
Trade debts44€2.4m€2.2m▼
Suppliers440/4€2.4m€2.2m▼
Advances received on contracts in progress46€0.005m€0.005m=
Taxes, remuneration and social security45€0.3m€0.2m▼
Taxes450/3€0.2m€0.03m▼
Remuneration and social security454/9€0.2m€0.2m▼
Other amounts payable47/48€0.7m€104▼
Income statement Code20242025
Operating income70/76A€11.0m€11.3m▲
Turnover70€10.7m€10.7m▲
Change in stocks of work in progress, finished goods and contracts in progress71-€0.3m
Own construction capitalised72€0€0.02m▲
Other operating income74€0.3m€0.3m▼
Operating charges60/66A€11.6m€11.4m▼
Goods for resale, raw materials and consumables60€6.1m€6.3m▲
Purchases600/8€6.0m€5.8m▼
Change in stocks: decrease (increase)609€0.2m€0.5m▲
Services and other goods61€3.0m€3.5m▲
Remuneration, social security and pensions62€2.0m€1.5m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.1m€0.09m▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.1m-€0.1m▼
Other operating charges640/8€0.02m€0.1m▲
Non-recurring operating charges66A€0.2m-
Operating profit (loss)9901-€0.5m-€0.07m▲
Financial income75/76B€1.5m€0.2m▼
Recurring financial income75€1.5m€0.2m▼
Income from current assets751€1.5m€0.001m▼
Other financial income752/9€0.006m€0.2m▲
Non-recurring financial income76B€327€17▼
Financial charges65/66B€1.8m€0.3m▼
Recurring financial charges65€1.8m€0.3m▼
Debt charges650€1.7m€0.05m▼
Other financial charges652/9€0.1m€0.3m▲
Profit (loss) for the period before taxes9903-€0.8m-€0.2m▲
Income taxes67/77-€0.001m€0.003m▲
Taxes670/3-€0.003m
Tax adjustments and reversals of tax provisions77€0.001m-
Profit (loss) for the period9904-€0.8m-€0.2m▲
Profit (loss) for the period to be appropriated9905-€0.8m-€0.2m▲
Appropriation of the result
Profit (loss) to be appropriated9906-€0.8m-€1.1m▼
Profit (loss) brought forward from the previous period14P--€0.8m
Transfer from equity791/2-€0.8m
From reserves792-€0.8m
Social balance sheet
Average headcount (FTE)908719.813.6▼

The notes to these accounts have 73 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 11-06-2026.

Line20182019202020212022202320242025Change
Operating income70/76A---€10.4m€7.3m€11.9m€11.0m€11.3m▲ 2.5%
Turnover70€11.1m€10.6m€15.7m€10.2m€7.2m€11.4m€10.7m€10.7m▲ 0.6%
Change in stocks of work in progress, finished goods and contracts in progress71-------€0.3m-
Own construction capitalised72-----€0.3m€0€0.02m-
Other operating income74---€0.2m€0.09m€0.2m€0.3m€0.3m▼ 20.8%
Non-recurring operating income76A---€0.004m-----
Operating charges60/66A---€10.9m€7.3m€12.2m€11.6m€11.4m▼ 1.6%
Goods for resale, raw materials and consumables60---€7.0m€4.3m€6.2m€6.1m€6.3m▲ 3.9%
Purchases600/8---€6.1m€4.5m€7.7m€6.0m€5.8m▼ 2.3%
Change in stocks: decrease (increase)609---€0.9m-€0.2m-€1.5m€0.2m€0.5m▲ 248%
Services and other goods61---€2.5m€2.1m€3.4m€3.0m€3.5m▲ 16.3%
Remuneration, social security and pensions62---€1.4m€0.9m€2.4m€2.0m€1.5m▼ 27.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.04m€0.04m€0.04m€0.04m€0.02m€0.06m€0.1m€0.09m▼ 21.7%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4----€0.08m-€0.03m€0.1m€0.1m-€0.1m-
Provisions for liabilities and charges: additions (uses and reversals)635/8----€0.004m-----
Other operating charges640/8---€0.009m€0.1m€0.03m€0.02m€0.1m▲ 474%
Non-recurring operating charges66A------€0.2m--
Operating profit (loss)9901€1.8m€1.8m€2.2m-€0.5m-€0.05m-€0.3m-€0.5m-€0.07m▲ 86.3%
Financial income75/76B---€0.7m€0.9m€1.5m€1.5m€0.2m▼ 88.7%
Recurring financial income75€0.2m€13.4m€1.8m€0.7m€0.9m€1.5m€1.5m€0.2m▼ 88.7%
Income from current assets751---€0.7m€0.9m€1.5m€1.5m€0.001m▼ 99.9%
Other financial income752/9---€0.004m€0.004m€0.008m€0.006m€0.2m▲ 27×
Non-recurring financial income76B----€499-€327€17▼ 94.9%
Financial charges65/66B---€6.7m€1.5m€8.6m€1.8m€0.3m▼ 81.9%
Recurring financial charges65€1.6m€1.5m€1.4m€1.2m€1.5m€2.9m€1.8m€0.3m▼ 81.9%
Debt charges650€1.4m€1.3m€1.2m€1.1m€1.4m€2.7m€1.7m€0.05m▼ 96.8%
Other financial charges652/9---€0.1m€0.1m€0.1m€0.1m€0.3m▲ 151%
Non-recurring financial charges66B---€5.5m-€5.7m---
Profit (loss) for the period before taxes9903€0.5m€13.7m€28.6m-€6.4m-€0.7m-€7.4m-€0.8m-€0.2m▲ 72.3%
Income taxes67/77€0.1m€0.3m€0.2m-€0.006m-€0.2m€0.004m-€0.001m€0.003m-
Taxes670/3----€0.002m€0.004m-€0.003m-
Tax adjustments and reversals of tax provisions77---€0.006m€0.2m-€0.001m--
Profit (loss) for the period9904€0.4m€13.3m€28.4m-€6.4m-€0.5m-€7.4m-€0.8m-€0.2m▲ 71.9%
Profit (loss) for the period to be appropriated9905€0.4m€13.3m€28.4m-€6.4m-€0.5m-€7.4m-€0.8m-€0.2m▲ 71.9%
Line20182019202020212022202320242025Change
Assets
Total assets20/58€59.4m€66.0m€90.1m€82.0m€53.1m€47.2m€16.0m€18.8m▲ 17.8%
Fixed assets21/28€51.2m€51.2m€12.6m€5.6m€13.0m€12.5m€12.4m€15.3m▲ 23.4%
Intangible fixed assets21€0.07m€0.05m€0.02m€0.007m€0.002m€0.3m€0.4m€0.3m▼ 22.4%
Tangible fixed assets22/27€0.07m€0.06m€0.04m€0.04m€0.03m€0.3m€0.04m€0.04m▼ 1.2%
Plant, machinery and equipment23---€0.04m€0.03m€0.03m€0.02m€0.02m▲ 8.0%
Furniture and vehicles24---€418€115€0.008m€0.005m€0.006m▲ 13.9%
Leasing and similar rights25-----€0---
Other tangible fixed assets26-----€0---
Assets under construction and advance payments27----€0.004m€0.2m€0.02m€0.02m▼ 12.3%
Financial fixed assets28€51.1m€51.1m€12.5m€5.5m€12.9m€12.0m€12.0m€15.0m▲ 25.0%
Affiliated companies280/1---€5.5m€12.9m€12.0m€12.0m€15.0m▲ 25.0%
Participating interests280---€5.5m€12.9m€12.0m€12.0m€15.0m▲ 25.0%
Other financial fixed assets284/8---€0.001m€0.001m€0.003m€0.003m€0.003m=
Amounts receivable and cash guarantees285/8---€0.001m€0.001m€0.003m€0.003m€0.003m=
Current assets29/58€8.2m€14.8m€77.5m€76.5m€40.1m€34.7m€3.5m€3.5m▼ 2.1%
Stocks and contracts in progress3€1.9m€2.0m€2.1m€1.2m€1.5m€2.9m€2.6m€2.5m▼ 5.5%
Stocks30/36---€1.2m€1.5m€2.9m€2.6m€2.5m▼ 5.5%
Raw materials and consumables30/31----€0.2m€1.0m€0.8m€0.8m▼ 1.4%
Work in progress32----€0.01m€64€0--
Finished goods33----€0.03m€0.2m€0.3m€0.5m▲ 103%
Goods purchased for resale34---€1.2m€1.2m€1.7m€1.6m€1.2m▼ 25.4%
Amounts receivable within one year40/41€2.8m€0.2m€75.3m€75.0m€38.5m€31.5m€0.7m€0.3m▼ 65.1%
Trade receivables40----€0.3m€0.4m€0.6m€0.3m▼ 55.5%
Other amounts receivable41---€75.0m€38.2m€31.1m€0.2m€0.001m▼ 99.5%
Current investments50/53--€0€0€0€0€0€0=
Own shares50---€0€0€0€0€0=
Cash at bank and in hand54/58€3.5m€12.6m€0.1m€0.2m€0.1m€0.3m€0.2m€0.7m▲ 320%
Deferred charges and accrued income490/1---€0.02m€0.009m€0.03m€0.01m€0.04m▲ 139%
Equity and liabilities
Total equity and liabilities10/49€59.4m€66.0m€90.1m€82.0m€53.1m€47.2m€16.0m€18.8m▲ 17.8%
Equity10/15€3.0m€9.4m€37.7m€31.3m€5.8m-€1.6m€12.6m€16.4m▲ 29.8%
Contributions10/11€1.7m€1.7m€1.7m€1.7m€1.7m€1.7m€9.3m€13.3m▲ 43.0%
Capital10---€1.7m€1.7m€1.7m€9.3m€13.3m▲ 43.0%
Issued capital100---€1.7m€1.7m€1.7m€9.3m€13.3m▲ 43.0%
Reserves13€1.4m€7.7m€36.1m€29.7m€4.2m€4.2m€4.2m€3.3m▼ 19.8%
Non-distributable reserves130/1---€1.3m€1.3m€1.3m€1.3m€1.3m=
Legal reserve130---€1.3m€1.3m€1.3m€1.3m€1.3m=
Own shares acquired1312---€0€0€0€0€0=
Tax-exempt reserves132---€0.02m€0.02m€0.02m€0.02m€0.02m=
Distributable reserves133---€28.4m€2.8m€2.8m€2.8m€2.0m▼ 28.9%
Profit (loss) carried forward14------€7.4m-€0.8m-€0.2m▲ 71.9%
Amounts payable17/49€56.4m€56.6m€52.3m€50.7m€47.3m€48.8m€3.3m€2.4m▼ 27.8%
Amounts payable within one year42/48€56.4m€56.6m€52.3m€50.7m€47.3m€48.8m€3.3m€2.4m▼ 27.8%
Current portion of amounts payable after more than one year42-----€0---
Financial debts43---€48.5m€44.9m€44.9m€0€0-
Other loans439---€48.5m€44.9m€44.9m€0€0-
Trade debts44€1.8m€1.7m€1.8m€1.7m€2.0m€2.5m€2.4m€2.2m▼ 5.7%
Suppliers440/4---€1.7m€2.0m€2.5m€2.4m€2.2m▼ 5.7%
Advances received on contracts in progress46---€0.005m€0.005m€0.005m€0.005m€0.005m=
Taxes, remuneration and social security45---€0.5m€0.3m€0.7m€0.3m€0.2m▼ 43.2%
Taxes450/3---€0.3m€0.1m€0.2m€0.2m€0.03m▼ 78.6%
Remuneration and social security454/9---€0.2m€0.2m€0.4m€0.2m€0.2m▼ 11.4%
Other amounts payable47/48---€0.004m-€0.7m€0.7m€104▼ 100.0%
Accrued charges and deferred income492/3---€0.001m-----
Line20182019202020212022202320242025Change
Profit (loss) for the period9904€0.4m€13.3m€28.4m-€6.4m-€0.5m-€7.4m-€0.8m-€0.2m▲ 71.9%
+ Depreciation and write-downs630€0.04m€0.04m€0.04m€0.04m€0.02m€0.06m€0.1m€0.09m▼ 21.7%
Operating cash flow (approximation)€0.4m€13.4m€28.4m-€6.4m-€0.5m-€7.3m-€0.7m-€0.1m▲ 80.2%
Investment in fixed assets (approximation)--€0.001m€38.6m€7.0m-€7.4m€0.4m-€0.002m-€3.0m▼ 156,581%
Change in cash-€9.1m-€12.5m€0.1m-€0.1m€0.1m-€0.1m€0.5m-

A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 49 filings with the National Bank
Financial year Type Filed Reference Document
31-12-2025 full format 11-06-2026 2026-00157374 PDF
31-12-2024 full format 15-09-2025 2025-00493685 PDF
31-12-2023 full format 07-06-2024 2024-00119284 PDF
31-12-2022 full format 05-06-2023 2023-00109744 PDF
31-12-2021 full format 31-05-2022 2022-20042942 PDF
31-12-2020 full format 25-05-2021 2021-15200233 PDF
31-12-2019 full format 31-05-2020 2020-13900411 PDF
31-12-2018 full format 23-05-2019 2019-14100048 PDF
31-12-2017 full format 23-05-2018 2018-13500082 PDF
31-12-2016 full format 09-05-2017 2017-11500389 PDF

Show all 49 filings

Board & ownership

Directors

Directors
3 directors, 1 in day-to-day management, no change since 2026

Board 3

Céline Caveye
Director · current term since 12-05-2021 · 6-year term from 2021 · listed in the 2025 annual accounts, filed on 11-06-2026
Current
Cornelia de Jong
Director · current term since 10-05-2022 · listed in the 2025 annual accounts, filed on 11-06-2026
Current
Padilla Rafael
Director · current term since 09-05-2023 · 6-year term from 2023 · listed in the 2025 annual accounts, filed on 11-06-2026
Current

Day-to-day management 1

Peter De Sutter
Day-to-day manager · appointed in the act of 21-05-2021
Current
Office holders in the KBO →
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“De Raad van Bestuur vertegenwoordigt als college de Vennootschap in alle handelingen in en buiten recht. Hij handelt door de meerderheid van…”
deed of 26-08-2024

Owners and capital

Shareholders

1 owner

Chain of control

  1. Fagron NV consolidates
  2. INFINITY PHARMA

Owners 1

Capital transactions

Capital over time
  1. 02-01-2026 Capital increase of €4,000,000 · to €13,300,000 · no new shares · in cash
  2. 23-01-2025 Capital increase of €15,009,359.36 · to €16,668,329.98 · no new shares · in cash
  3. 23-01-2025 Capital reduction of €7,368,329.98 · to €9,300,000 · “aanzuivering van verliezen”
  4. 26-07-2021 Capital stated in the deed · €1,658,970.62 · 1,366,595 shares
  5. 10-07-2018 Capital increase of €99,873.22 · to €799,872.46 · 170,635 new shares
  6. 10-07-2018 Capital increase of €859,098.16 · to €1,658,970.62 · no new shares
  7. 30-11-2017 Capital reduction of €186,169,363.76 · to €699,999.24 · “uitkering in natura van een deel van de ... vordering”
  8. 05-05-2014 Capital increase of €133,977,156 · to €186,869,363 · 857,451 new shares · schuldvordering
Show 1 older capital entries
  1. 02-03-2010 Capital stated in the deed · €52,892,207

Mandate history

22 people, 4 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • began earlier
  • end not dated
Mandates per person, with start and end dates
Name Functions and periods
Céline Caveye
  • Director, appointed in the act of 22-11-2016, still in office
Cornelia de Jong
  • Director, appointed in the act of 20-12-2016, still in office
  • Managing director, appointed in the act of 08-02-2018, last mentioned in 2018
Padilla Rafael
  • Director, appointed in the act of 08-02-2018, still in office
Peter De Sutter
  • Day-to-day manager, appointed in the act of 21-05-2021, still in office
Johan Verlinden
  • Director, appointed in the act of 22-11-2016, until 07-07-2026
De Jong Cormelia Neeltje (gezegd Karin)
  • Director, from before 10-05-2022, no longer listed in the 2025 annual accounts
Bart Ameije
  • Day-to-day manager, appointed in the act of 26-11-2019, until 01-04-2021
Hernando Acosta
  • Day-to-day manager, appointed in the act of 19-11-2020, until 01-03-2021
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
  • Statutory auditor, appointed in the act of 16-10-2019, no longer listed in the 2025 annual accounts
PricewaterhouseCoopers Reviseurs d'Entreprises
  • Statutory auditor, appointed in the act of 22-09-2010, until 16-10-2019
Jumoo bvba
  • Day-to-day manager, appointed in the act of 04-10-2017, until 25-03-2019
Johannes Stols
  • Director, appointed in the act of 23-03-2016, until 04-12-2017
  • Managing director, appointed in the act of 23-03-2016, ended, last mentioned on 23-03-2016
Kalman Petro
  • Day-to-day manager, appointed in the act of 31-05-2017, until 01-09-2017
Davy De Vlieger
  • Day-to-day manager, appointed in the act of 31-05-2017, until 01-06-2017
BOUVRY Christophe
  • Day-to-day manager, appointed in the act of 20-12-2016, until 01-04-2017
Procuram bvba
  • Day-to-day manager, appointed in the act of 17-07-2014, until 01-04-2017
Tim Delameilleure
  • Day-to-day manager, appointed in the act of 20-12-2016, until 01-04-2017
JAN PEETERS
  • Director, from before 14-05-2013 to 17-10-2016
  • Managing director, appointed in the act of 06-02-2014, last mentioned in 2014
Rony Lebotte
  • Day-to-day manager, appointed in the act of 26-02-2014, until 17-10-2016
Gerardus van Jeveren
  • Director, appointed in the act of 06-02-2014, until 12-12-2015
  • Director and managing director, until 12-12-2015
BVBA ROMANI MANAGEMENT
  • Day-to-day manager, appointed in the act of 26-02-2014, until 25-04-2014
SCCRL PricewaterhouseCoupers
  • Réviseurs d'entreprises, appointed in the act of 22-06-2007, until 22-09-2010
See the board, name and registered office on a given date →

Articles of association

Board ruleThese rules set how the board is made up, meets and takes decisions.
“Toevoeging na bestaande tekst, 15”

Articles of association, deed of 07-07-2026 (in Dutch)

Network & group

Holdings and subsidiaries

3 holdings

Holdings 3

Source for every holding own accounts 2025

Former holdings (2)

Acquisitions and mergers

8 transactions
Took over:PHARMA-PACK
BE 0426.468.517Gazette deed of 08-08-2023 (4 acts)
Took over:INFINITY PHARMA
BE 0883.273.090operation treated as a merger by absorption · Gazette deed of 26-07-2021 (2 acts)
Took over:ARSEUS BELGIË
BE 0434.900.191Gazette deed of 13-08-2020 (2 acts)
BE 0456.622.154Gazette deed of 27-12-2018 (2 acts)
Took over:BELGOPHAR
BE 0860.437.213Gazette deed of 27-12-2018 (2 acts)
Took over:EUPHACO
BE 0542.502.588merger by absorption · Gazette deed of 10-07-2018 (2 acts)
Took over:A.C.A. - PHARMA
BE 0416.121.783operation treated as a merger by absorption · Gazette deed of 20-04-2011
BE 0414.436.656merger by absorption · Gazette deed of 02-01-2006 · effective 07-12-2005

Companies at the same address

4 other companies

Connections & network

14 connected companies
Depth
Belgian Association of Consumer Healthcare Industry, Shared director BABelgianAssociation…Belmont Food, Shared director BFBelmont FoodFEDERATION DE L'INDUSTRIE ALIMENTAIRE - FEDERATIE VOEDINGSINDUSTRIE, Shared director FDFEDERATION DEL'INDUSTRIE…GAIN TIME, Shared director GTGAIN TIMEGREEN MONKEY, Shared director GMGREEN MONKEYisomasters, Shared director IisomastersKINGSPAN, Shared director KKINGSPANMake-A-Wish Belgium - Vlaanderen, Shared director MBMake-A-WishBelgium…RAAL LA LOUVIERE, Shared director RLRAAL LALOUVIERECCR Partners II, Shared corporate director CPCCR PartnersIIFAGRON CAPITAL, Shared corporate director FCFAGRON CAPITALLunch Garden Belgium, Shared corporate director LGLunch GardenBelgiumNOBEL, Shared corporate director NNOBELSOFT 33, Shared corporate director S3SOFT 33INFINITY PHARMA INFINITYPHARMA0416.616.681
Shared directors
This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Belgian Association of Consumer Healthcare Industry
Shared director
→
Belmont Food
Shared director
→
FEDERATION DE L'INDUSTRIE ALIMENTAIRE - FEDERATIE VOEDINGSINDUSTRIE
Shared director
→
GAIN TIME
Shared director
→
Show 10 more companies with a shared director
GREEN MONKEY
Shared director
→
isomasters
Shared director
→
KINGSPAN
Shared director
→
Make-A-Wish Belgium - Vlaanderen
Shared director
→
RAAL LA LOUVIERE
Shared director
→
CCR Partners II
Shared corporate director
→
FAGRON CAPITAL
Shared corporate director
→
Lunch Garden Belgium
Shared corporate director
→
NOBEL
Shared corporate director
→
SOFT 33
Shared corporate director
→

Timeline

Acts, filings and financial milestones

Deadline for the 2026 accounts: 31-07-2027
2026
07-07
Gazette deed Company renamed from PHARMA-PACK to Infinity Pharma
Resignation: VERLINDEN Johan (director) · Power of attorney5 points ▸
  • General meeting, 29-06-2026
  • Name change, Infinity Pharma
  • Director resignation, VERLINDEN Johan (director)
  • Power of attorney
  • Power of attorney, Stijn RAES

Open the act in the Belgian Official Gazette

11-06
NBB filing Annual accounts 2025 filedPDF
full format · 50 days before the deadline
02-01
Gazette deed Capital increase of €4,000,000 to €13,300,000
Amendment of the articles · Power of attorney7 points ▸
  • General meeting, 16-12-2025
  • Capital increase, €4,000,000
  • Capital contribution
  • Capital, €13,300,000
  • Amendment of the articles, 5
  • Power of attorney
  • Power of attorney, Stijn RAES

Open the act in the Belgian Official Gazette

2025
31-12
Gazette deed Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)
Permanent representative: Lien Winne3 points ▸
  • General meeting, 06-10-2025
  • Auditor appointment, PwC Bedrijfsrevisoren BV (statutory auditor)
  • Permanent representative, Lien Winne

Open the act in the Belgian Official Gazette

15-09
NBB filing Annual accounts 2024 filedPDF
full format · 46 days late
23-01
Gazette deed Capital & shares
Capital increase · Capital contribution · Capital decrease10 points ▸
  • General meeting, “handelend in de plaats van de algemene vergadering, buitengewone algemene vergadering” (deed in Dutch)
  • Capital increase, €15,009,359.36
  • Capital contribution, €15,009,359.36
  • Capital decrease, €7,368,329.98
  • Amendment of the articles, 5
  • Capital, €9,300,000
  • Power of attorney
  • Power of attorney, Stijn RAES
  • Other provision, “DERDE BESLUIT: Vaststelling van de verwezenlijking van de kapitaalverhoging” (deed in Dutch)
  • Other provision, “VIJFDE BESLUIT: Vaststelling van de verwezenlijking van de kapitaalvermindering” (deed in Dutch)

Open the act in the Belgian Official Gazette

2024
31-12
Financial Equity above €10mequity €12.6m
Equity rises from -€1.6m to €12.6m.
26-08
Gazette deed Reappointment: Padilla Rafael (director)
2 points ▸
  • General meeting, 09-05-2023
  • Director reappointment, Padilla Rafael (director)

Open the act in the Belgian Official Gazette

07-06
NBB filing Annual accounts 2023 filedPDF
full format · 54 days before the deadline
2023
31-12
Financial Weakest financial yearnet -€7.4m
The net result drops to -€7.4m, the lowest from 2018 to 2025. It recovers the following year.
03-08
Gazette deed Merger: INFINITY PHARMA takes over PHARMA-PACK
Company renamed from INFINITY PHARMA to PHARMA-PАСК3 points ▸
  • General meeting, “buitengewone algemene vergadering van de aandeelhouders, geldig vertegenwoordigd ingevolge onderhandse volmachten” (deed in Dutch)
  • Merger, “alle activa en passiva van haar vermogen,niets uitgezonderd noch voorbehouden, met fusie door overneming gelijkgestelde verrichting” (deed in Dutch)
  • Name change, PHARMA-PАСК

Open the act in the Belgian Official Gazette

05-06
NBB filing Annual accounts 2022 filedPDF
full format · 56 days before the deadline
Show earlier events
03-05
Gazette deed Merger proposal: INFINITY PHARMA takes over Pharma-Pack
Board composition · Accounting effect12 points ▸
  • Board meeting, 01-04-2023, mentioned 2 times in the deed
  • Merger, “gehele vermogen,actief en passief, algemene vergaderingen van deelnemende vennootschappen” (deed in Dutch)
  • Board composition, Rafael Padilla (director), mentioned 2 times in the deed
  • Board composition, Cornelia Neeltje de Jong (director), mentioned 2 times in the deed
  • Board composition, Johan Verlinden (director)
  • Board composition, Céline Caveye (director)
  • Other provision, “kennisname neerleggingsverplichting fusievoorstel, minstens 6 weken voor algemene vergadering die zich over fusie moet uitspreken” (deed in Dutch)
  • Accounting effect, 01-01-2023
  • Other provision, “aandeelhouders met bijzondere rechten en houders van andere effecten dan aandelen in Over te Nemen Vennootschap” (deed in Dutch)
  • Other provision, “bijzondere voordelen leden bestuursorganen Overnemende en Over te Nemen Vennootschap” (deed in Dutch)
  • Other provision, “fusie- en revisoraal verslag” (deed in Dutch)
  • Other provision, “aanpassing voorwerp en overige statutaire bepalingen Overnemende Vennootschap naar aanleiding van fusie” (deed in Dutch)

Open the act in the Belgian Official Gazette

2022
22-12
Gazette deed Appointments: Johan Verlinden (director) and Céline Caveye (director)
4 points ▸
  • General meeting, 11-05-2021
  • Director appointment, Johan Verlinden (director)
  • Director appointment, Céline Caveye (director)
  • Other provision, “front page caption for instrumenting notary or authorised representative” (deed in Dutch)

Open the act in the Belgian Official Gazette

22-12
Gazette deed Reappointments: De Jong Cormelia Neeltje (gezegd Karin) (director) and Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
Approval · Director discharge9 points ▸
  • General meeting, 10-05-2022
  • Other provision, “bespreking verslag Raad van Bestuur en verslag commissaris over jaarrekening boekjaar 2021, geen opmerkingen” (deed in Dutch)
  • Approval, “Raad van Bestuur”, 31-12-2021 (deed in Dutch)
  • Other provision, “bestemming resultaat boekjaar afgesloten op 31-12-2021”, EUR (deed in Dutch)
  • Director reappointment, De Jong Cormelia Neeltje (gezegd Karin) (director)
  • Auditor reappointment, Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
  • Other provision, “vertegenwoordigt Deloitte Bedrijfsrevisoren CVBA als Commissaris, vertegenwoordiging commissaris” (deed in Dutch)
  • Director discharge, Deloitte Bedrijfsrevisoren CVBA
  • Director discharge, alle bestuurders

Open the act in the Belgian Official Gazette

31-05
NBB filing Annual accounts 2021 filedPDF
full format · 61 days before the deadline
2021
26-07
Gazette deed Merger: ACA PHARMA takes over INFINITY PHARMA
Company renamed from ACA PHARMA to INFINITY PHARMA · Amendment of the articles · Capital6 points ▸
  • Merger, “met fusie door overneming gelijkgestelde verrichting” (deed in Dutch)
  • Name change, INFINITY PHARMA
  • Amendment of the articles, mentioned 2 times in the deed
  • Capital, €1,658,970.62
  • Power of attorney, DELAMEILLEURE Tim
  • Power of attorney, CLETY Franck

Open the act in the Belgian Official Gazette

25-05
NBB filing Annual accounts 2020 filedPDF
full format · 67 days before the deadline
21-05
Gazette deed 1 director appointed, 2 directors resigning
Resignations: Hernando Acosta (day-to-day manager) and Bart Ameije (day-to-day manager) · Appointment: Peter De Sutter (day-to-day manager) · Director discharge5 points ▸
  • Director resignation, Hernando Acosta (day-to-day manager)
  • Director resignation, Bart Ameije (day-to-day manager)
  • Director discharge, Hernando Acosta
  • Director discharge, Bart Ameije
  • Director appointment, Peter De Sutter (day-to-day manager)

Open the act in the Belgian Official Gazette

27-04
Gazette deed Merger proposal: ACA PHARMA takes over Infinity Pharma
Power of attorney · Accounting effect5 points ▸
  • Board meeting, 01-04-2021
  • Power of attorney, Tim Delameilleure
  • Power of attorney, Franck Cléty
  • Merger
  • Accounting effect, 01-01-2021

Open the act in the Belgian Official Gazette

2020
31-12
Financial Highest result from 2018 to 2025net €28.4m ▲113%
The operating result of €2.2m and the net result of €28.4m are both a record.
31-12
Financial Liquidity more than 5 timescurrent ratio 1.48
The current ratio rises from 0.26 to 1.48. Short-term debt falls from €56.6m to €52.3m.
31-12
Financial Equity above €25mequity €37.7m ▲303%
With a profit in every financial year since 2018, equity grows to €37.7m.
19-11
Gazette deed Appointment: Hernando Acosta (day-to-day manager)
2 points ▸
  • Board meeting, 01-10-2020
  • Director appointment, Hernando Acosta (day-to-day manager)

Open the act in the Belgian Official Gazette

13-08
Gazette deed Merger: ACA PHARMA takes over ARSEUS BELGIË
Net-asset statement2 points ▸
  • Merger
  • Net-asset statement, 31-12-2019

Open the act in the Belgian Official Gazette

10-06
Gazette deed Merger proposal: ACA PHARMA takes over Arseus België NV
Power of attorney · Accounting effect5 points ▸
  • Board meeting, 28-05-2020
  • Merger
  • Power of attorney, Tim Delameilleure
  • Power of attorney, Franck Cléty
  • Accounting effect, 01-01-2020

Open the act in the Belgian Official Gazette

31-05
NBB filing Annual accounts 2019 filedPDF
full format · 61 days before the deadline
2019
31-12
Financial Equity above €5mequity €9.4m ▲209%
With a profit in every financial year since 2018, equity grows to €9.4m.
26-11
Gazette deed Appointment: Bart Ameije (day-to-day manager)
2 points ▸
  • Board meeting, 01-09-2019
  • Director appointment, Bart Ameije (day-to-day manager)

Open the act in the Belgian Official Gazette

16-10
Gazette deed Appointment: Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
Permanent representative: Ine Nuyts3 points ▸
  • General meeting, 24-06-2019
  • Auditor appointment, Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
  • Permanent representative, Ine Nuyts

Open the act in the Belgian Official Gazette

05-06
Gazette deed Resignation: Jumoo bvba (day-to-day manager)
Director discharge3 points ▸
  • Board meeting, 25-03-2019
  • Director resignation, Jumoo bvba (day-to-day manager)
  • Director discharge, Jumoo bvba

Open the act in the Belgian Official Gazette

23-05
NBB filing Annual accounts 2018 filedPDF
full format · 69 days before the deadline
2018
27-12
Gazette deed Merger: ACA PHARMA takes over BELGOPHAR
Net-asset statement · Power of attorney4 points ▸
  • Merger, mentioned 2 times in the deed
  • Net-asset statement, 31-08-2018
  • Power of attorney, Tim DELAMEILLEURE
  • Power of attorney, Katja VAN DALSEN

Open the act in the Belgian Official Gazette

17-10
Gazette deed Merger proposal: ACA Pharma NV takes over Accessoires Et Produits Pharmaceutiques En Gros NV
Power of attorney · Accounting effect5 points ▸
  • Board meeting, 06-09-2018
  • Power of attorney, Tim Delameilleure
  • Power of attorney, Katja van Dalsen
  • Merger
  • Accounting effect, 01-09-2018

Open the act in the Belgian Official Gazette

17-10
Gazette deed Merger proposal: ACA Pharma NV takes over Belgophar BVBA
Power of attorney · Accounting effect4 points ▸
  • Merger
  • Power of attorney, Tim Delameilleure
  • Power of attorney, Katja van Dalsen
  • Accounting effect, 01-09-2018

Open the act in the Belgian Official Gazette

10-07
Gazette deed Merger: ACA PHARMA takes over EUPHACO
Capital increase · Amendment of the articles · Power of attorney7 points ▸
  • General meeting, 11-06-2018
  • Merger, “absorption”, 31-12-2017 (deed in Dutch)
  • Capital increase, €99,873.22
  • Capital increase, €859,098.16
  • Amendment of the articles
  • Power of attorney, Tim DELAMEILLEURE
  • Power of attorney, Katja VAN DALSEN

Open the act in the Belgian Official Gazette

23-05
NBB filing Annual accounts 2017 filedPDF
full format · 69 days before the deadline
24-04
Gazette deed Merger proposal: ACA Pharma NV takes over Euphaco NV
Appointment: PwC Bedrijfsrevisoren BCVBA (statutory auditor) · Power of attorney · Net-asset statement12 points ▸
  • Board meeting, 19-03-2018
  • Merger
  • Power of attorney, Tim Delameilleure, mentioned 2 times in the deed
  • Power of attorney, Katja van Dalsen, mentioned 2 times in the deed
  • Net-asset statement, 31-12-2017, mentioned 2 times in the deed
  • Share issue, 170.635
  • Accounting effect, 01-01-2018
  • Auditor appointment, PwC Bedrijfsrevisoren BCVBA
  • Auditor fee, 7.000, EUR
  • Dissolution, “zonder vereffening” (deed in Dutch)
  • Exchange ratio, “per share”, 5,62 (deed in Dutch)
  • Exchange ratio, “per share”, 799,14 (deed in Dutch)

Open the act in the Belgian Official Gazette

08-02
Gazette deed 2 directors appointed, 1 director resigning
Resignation: Johannes Stols (director) · Appointments: Rafael Padilla (director) and Cornelia de Jong (managing director) · Director discharge7 points ▸
  • General meeting, 04-12-2017
  • Board meeting, 04-12-2017
  • Director resignation, Johannes Stols (director)
  • Director discharge, Johannes Stols
  • Director appointment, Rafael Padilla (director)
  • Mandate compensation, Rafael Padilla
  • Director appointment, Cornelia de Jong (managing director)

Open the act in the Belgian Official Gazette

2017
04-12
Gazette deed Capital & shares · Miscellaneous
General meeting1 point ▸
  • General meeting, 25-10-2017

Open the act in the Belgian Official Gazette

30-11
Gazette deed Capital decrease of €186,169,363.76
Amendment of the articles · Power of attorney4 points ▸
  • General meeting, 31-10-2017
  • Capital decrease, €186,169,363.76
  • Amendment of the articles
  • Power of attorney, Johan VERLINDEN

Open the act in the Belgian Official Gazette

04-10
Gazette deed 1 director appointed, 1 director resigning
Resignation: Kalman Petro (day-to-day manager) · Appointment: Jumoo bvba (day-to-day manager) · Permanent representative: Daan Vermeulen6 points ▸
  • General meeting, 28-08-2017
  • Director resignation, Kalman Petro (day-to-day manager)
  • Director appointment, Jumoo bvba (day-to-day manager)
  • Permanent representative, Daan Vermeulen
  • Mandate compensation, Jumoo bvba
  • Mandate limit, 100.000 EUR

Open the act in the Belgian Official Gazette

26-07
Gazette deed Resignation: Davy de Vlieger (day-to-day manager)
2 points ▸
  • Board meeting, 01-06-2017
  • Director resignation, Davy de Vlieger (day-to-day manager)

Open the act in the Belgian Official Gazette

31-05
Gazette deed 2 directors appointed, 3 directors resigning
Resignations: Procuram bvba, Christophe Bouvry and Tim Delameilleure · Appointments: Kalman Petro (day-to-day manager) and Davy de Vlieger (day-to-day manager) · Mandate compensation11 points ▸
  • Board meeting, 31-03-2017
  • Director resignation, Procuram bvba (day-to-day manager)
  • Director resignation, Christophe Bouvry (day-to-day manager)
  • Director resignation, Tim Delameilleure (day-to-day manager)
  • Director appointment, Kalman Petro (day-to-day manager)
  • Director appointment, Davy de Vlieger (day-to-day manager)
  • Mandate compensation, Kalman Petro
  • Mandate compensation, Davy de Vlieger
  • Financial authorization, 500.000 EUR
  • Financial authorization, 100.000
  • Right of substitution, yes

Open the act in the Belgian Official Gazette

09-05
NBB filing Annual accounts 2016 filedPDF
full format · 83 days before the deadline
26-04
Gazette deed Appointment: BCVBA PwC Bedrijfsrevisoren (statutory auditor)
Permanent representative: Peter Van den Eynde · Mandate term4 points ▸
  • General meeting, 30-06-2016
  • Auditor appointment, BCVBA PwC Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Peter Van den Eynde
  • Mandate term, “na de algemene vergadering der aandeelhouders die de jaarekening per 31-12-2018 dient goed te keuren” (deed in Dutch)

Open the act in the Belgian Official Gazette

2016
20-12
Gazette deed 3 directors appointed, 2 directors resigning
Resignations: Jan Peeters nv (director) and Rony Lebotte (day-to-day manager) · Appointments: Cornelia de Jong, Christophe Bouvry and Tim Delameilleure · Director discharge9 points ▸
  • General meeting, 17-10-2016
  • Director resignation, Jan Peeters nv (director)
  • Director discharge, Jan Peeters nv (director)
  • Director appointment, Cornelia de Jong (director)
  • Mandate compensation, Cornelia de Jong
  • Director appointment, Christophe Bouvry (day-to-day manager)
  • Director appointment, Tim Delameilleure (day-to-day manager)
  • Director resignation, Rony Lebotte (day-to-day manager)
  • Financial limit, 1.000.000 EUR

Open the act in the Belgian Official Gazette

22-11
Gazette deed Appointments: Johan Verlinden (director) and Céline Caveye (director)
3 points ▸
  • General meeting, 22-06-2016
  • Director appointment, Johan Verlinden (director)
  • Director appointment, Céline Caveye (director)

Open the act in the Belgian Official Gazette

15-06
Gazette deed Miscellaneous
Change of control2 points ▸
  • General meeting, 30-05-2016
  • Change of control, “wijziging van controle” (deed in French)

Open the act in the Belgian Official Gazette

10-05
Gazette deed Registered office moved from Waregem to Nazareth
New seat: Venecoweg 20A, 9810 Nazareth · Previous seat: Textielstraat 24, 8790 Waregem · Permanent representative: Jan Peeters3 points ▸
  • Board meeting, 29-02-2016
  • Registered-office move, Venecoweg 20A, 9810 Nazareth
  • Permanent representative, Jan Peeters

Open the act in the Belgian Official Gazette

23-03
Gazette deed Resignation: Gerardus van Jeveren (director and managing director)
Appointment: Johannes Stols (director)5 points ▸
  • General meeting, 12-12-2015
  • Board meeting, 12-12-2015
  • Director resignation, Gerardus van Jeveren (director and managing director)
  • Director appointment, Johannes Stols (director)
  • Director appointment, Johannes Stols (managing director)

Open the act in the Belgian Official Gazette

2015
04-02
Gazette deed Miscellaneous
Change of control2 points ▸
  • General meeting, 10-12-2014
  • Change of control, “Wijziging van controle” (deed in Dutch)

Open the act in the Belgian Official Gazette

2014
17-07
Gazette deed 2 directors appointed, 1 director resigning
Resignation: Romani Management BVBA (day-to-day manager) · Permanent representatives: Filip Hoornaert and Michael Hillaert · Appointments: Procuram bvba (day-to-day manager) and Rony Lebotte (day-to-day manager)8 points ▸
  • Board meeting, 25-04-2014
  • Director resignation, Romani Management BVBA (day-to-day manager)
  • Director discharge, Romani Management BVBA
  • Permanent representative, Filip Hoornaert
  • Director appointment, Procuram bvba (day-to-day manager)
  • Director appointment, Rony Lebotte (day-to-day manager)
  • Permanent representative, Michael Hillaert
  • Financial limit, 1.000.000 EUR, mentioned 2 times in the deed

Open the act in the Belgian Official Gazette

21-05
Gazette deed Capital & shares
Amendment of the articles · Power of attorney3 points ▸
  • General meeting, 11-04-2014
  • Amendment of the articles
  • Power of attorney, Susana González Melón

Open the act in the Belgian Official Gazette

05-05
Gazette deed Capital increase of €133,977,156
Amendment of the articles · Power of attorney4 points ▸
  • General meeting, 25-03-2014
  • Capital increase, €133,977,156
  • Amendment of the articles
  • Power of attorney, Rony LEBOTTE

Open the act in the Belgian Official Gazette

26-02
Gazette deed 2 directors appointed
Appointments: Romani Management BVBA (day-to-day manager) and Rony Lebotte (day-to-day manager) · Permanent representative: Filip Hoornaert · Financial limit5 points ▸
  • Board meeting
  • Director appointment, Romani Management BVBA (day-to-day manager)
  • Director appointment, Rony Lebotte (day-to-day manager)
  • Permanent representative, Filip Hoornaert
  • Financial limit, 1000000 EUR, mentioned 2 times in the deed

Open the act in the Belgian Official Gazette

06-02
Gazette deed Appointment: BCVBA PwC Bedrijfsrevisoren (statutory auditor)
Permanent representative: Peter Van den Eynde · Mandate term4 points ▸
  • General meeting, 14-05-2013
  • Auditor appointment, BCVBA PwC Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Peter Van den Eynde
  • Mandate term, “na de algemene vergadering der aandeelhouders die de jaarrekening per 31-12-2015 dient goed te keuren” (deed in Dutch)

Open the act in the Belgian Official Gazette

2012
03-07
Gazette deed Capital & shares
Amendment of the articles2 points ▸
  • General meeting, 11-06-2012
  • Amendment of the articles

Open the act in the Belgian Official Gazette

2011
20-04
Gazette deed Merger: CERTA takes over A.C.A. - PHARMA
Company renamed to ACA PHARMA · Power of attorney5 points ▸
  • General meeting, “april 2011” (deed in Dutch)
  • Merger, “met fusie door overneming gelijkgestelde verrichting” (deed in Dutch)
  • Name change, ACA PHARMA
  • Power of attorney, Ann DE SMEDT
  • Power of attorney, Rony LEBOTTE

Open the act in the Belgian Official Gazette

24-02
Gazette deed Merger proposal with Certa
1 point ▸
  • Merger, “absorption” (deed in Dutch)

Open the act in the Belgian Official Gazette

2010
21-12
Gazette deed Capital & shares
Change of control2 points ▸
  • General meeting, 06-12-2010
  • Change of control, “true” (deed in Dutch)

Open the act in the Belgian Official Gazette

22-09
Gazette deed Appointment: PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
Permanent representative: Peter Opsomer · Power of attorney4 points ▸
  • General meeting, 11-05-2010
  • Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Peter Opsomer
  • Power of attorney, BV BVBA Peter Opsomer

Open the act in the Belgian Official Gazette

02-03
Gazette deed Amendment of the articles
Capital · Language change3 points ▸
  • General meeting, 12-02-2010
  • Capital, €52,892,207
  • Language change, “van het Franse naar het Nederlandse taalgebied” (deed in Dutch)

Open the act in the Belgian Official Gazette

12-01
Gazette deed Name · End & cessation
Amendment of the articles3 points ▸
  • General meeting, 22-12-2009
  • Corporate decision, “Annulation de la décision de modifier la dénomination de la société prise le 14-10-2009” (deed in French)
  • Amendment of the articles

Open the act in the Belgian Official Gazette

2009
09-11
Gazette deed Company renamed to ACA PHARMA
Registered office moved from Braine-l'Alleud to Waregem · New seat: 8790 Waregem, Textielstraat 24 · Previous seat: 1420 Braine-l'Alleud, Avenue du Commerce, 234 points ▸
  • General meeting, 14-10-2009
  • Name change, ACA PHARMA
  • Registered-office move, 8790 Waregem, Textielstraat 24
  • Amendment of the articles, mentioned 2 times in the deed

Open the act in the Belgian Official Gazette

2007
01-10
Gazette deed Assemblee Generale
General meeting1 point ▸
  • General meeting, 20-09-2007

Open the act in the Belgian Official Gazette

22-06
Gazette deed Appointment: SCCRL PricewaterhouseCoupers (réviseurs d'entreprises)
2 points ▸
  • General meeting, 30-03-2007
  • Auditor appointment, SCCRL PricewaterhouseCoupers (réviseurs d'entreprises)

Open the act in the Belgian Official Gazette

2006
02-01
Gazette deed Merger: CERTA takes over VERRERIE VERVIÉTOISE
Dissolution · Power of attorney · Reference date5 points ▸
  • Merger, 07-12-2005
  • Dissolution, 07-12-2005
  • Power of attorney, Rony LEBOTTE
  • Reference date, 30-06-2005
  • The company is a shareholder of VERRERIE VERVIÉTOISE

Open the act in the Belgian Official Gazette

2005
10-10
Gazette deed Merger proposal with Certa
1 point ▸
  • Merger, 26-09-2005

Open the act in the Belgian Official Gazette

24-01
Gazette deed Capital & shares · Amendment of the articles · Resignations & appointments
2 points ▸
  • General meeting, 29-12-2004
  • Amendment of the articles, mentioned 4 times in the deed

Open the act in the Belgian Official Gazette

Show all 49 filings

Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.An act published in both Dutch and French appears here once.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

History

INFINITY PHARMA was incorporated on 8 December 1976.1 Between 2005 and 2023 the company absorbed 8 companies by merger, including INFINITY PHARMA and PHARMA-PACK.234 The name was changed to ACA PHARMA in 2009 and to Infinity Pharma in 2026.56 The registered office moved to Waregem in 2009 and to Nazareth in 2016.57 Between 2014 and 2026 the capital was increased 4 times, most recently to €13.3m.8910 The board currently has 3 members. Céline Caveye has served longest, since 2021.11 Turnover went from €11.4m in 2023 to €10.7m in 2025 and headcount from 19.1 to 13.6 full-time equivalents.12

  1. 1KBO register
  2. 2Belgian Official Gazette, 02-01-2006
  3. 3Belgian Official Gazette, 26-07-2021
  4. 4Belgian Official Gazette, 08-08-2023
  5. 5Belgian Official Gazette, 09-11-2009
  6. 6Belgian Official Gazette, 07-07-2026
  7. 7Belgian Official Gazette, 10-05-2016
  8. 8Belgian Official Gazette, 05-05-2014
  9. 9Belgian Official Gazette, 23-01-2025
  10. 10Belgian Official Gazette, 02-01-2026
  11. 11National Bank, annual accounts 2025
  12. 12National Bank, annual accounts 2023 and 2025

Company details

Register details

Identity

KBO record
Name INFINITY PHARMA in Dutch
Former names PHARMA-PACK until 01-07-2026 · act of 07-07-2026
ACA PHARMA until 03-06-2021 · act of 26-07-2021
Enterprise number 0416.616.681
Legal form Public limited company
Status Active, normale toestand
Founded 08-12-1976
Entity type Legal entity

Registered office and establishments

Registered office Venecoweg 20A, 9810 Nazareth-De Pinte, Belgium
2 former offices
  • Textielstraat 24, 8790 Waregem until 29-02-2016 · act of 10-05-2016
  • 1420 Braine-l'Alleud until 01-01-2010 · act of 09-11-2009
Establishment unit Infinity Pharma NV, Venecoweg 20A, 9810 Nazareth-De Pinte since 31-03-1992 · unit number 2.013.193.230

Activities

NACEBEL 2025
VAT activities
46460 Wholesale of pharmaceutical and medical goods main activity
Social security (RSZ) activities
46460 Wholesale of pharmaceutical and medical goods main activity
Codes under NACEBEL 2008
VAT activities
46460 Wholesale trade main activity
Social security (RSZ) activities
46460 Wholesale trade main activity
Codes under NACEBEL 2003
51460 main activity
Joint committees 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid
116 Paritair Comité voor de scheikundige nijverheid annual accounts 2025
PurposeThe purpose describes the activities the company may carry out under its articles.
“De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de…”
2 activities
  1. De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de verkoop, de handel, de vertegenwoordiging, de makelarij, de opslag van allerhande chemische producten en andere, al dan niet therapeutisch, farmaceutisch, farmacologisch, de handel, de import van allerhande producten, gereedschappen, apparaten en extracten, parfums, schoonheidsproducten, aromatherapie, allerhande voedingsmiddelen, therapeutische middelen voor mensen, dieren en planten.
  2. Zij mag alle samenhangende handels-en nijverheidsverrichtingen stellen die kunnen bijdragen tot de ontwikkeling van haar onderneming en in het algemeen alle roerende, onroerende en financiële verrichtingen stellen en onder om het even welke vorm deelnemen aan alle ondernemingen waarvan het voorwerp aanverwant is aan of samenhangend is met het hare..
deed of 03-05-2023 (in Dutch)

Invoicing and payment

VAT number BE 0416.616.681
E-invoicing via Peppol
Reachable via Peppol
Peppol ID 0208:0416616681
Registered 01-10-2025

Follow this company and you will hear the next morning if it leaves the Peppol register.

Register as of 3 November 2026 · Peppol Directory

Financial year and general meeting

Accounts at the NBB
Financial year end 31-12

Recognitions · licences · registrations

Food safety, FASFC

1 site
Nazareth-De Pinteunit number 2.013.193.230
1 permission
Groothandelaar LM>3 maand · since 23-06-2023

Sites & property

Location
registered office establishment The establishment unit on the map
5 companies at this address See who is registered here

Buildings and parcels at the address

Ground area
1.6 ha
Building footprint
7,285 m²
Building volume
70,207 m³
Cadastral parcel Region Area Buildings Height / floors
44048A0094/00L000 Flanders 1.6 ha 1 · 7,284 m² 21.6 m · 2

We would like to set cookies. That happens only with your consent. What we measure